

September 21, 2023

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street, Fort, Mumbai – 400 001

Ref: Scrip Code: 532296

Dear Sir/Madam,

Sub: Clarification/Confirmation on news item appearing in “Media/Publication”

We refer to the clarification sought by the BSE from the Company on September 21, 2023 in relation to a news article on www.moneycontrol.com dated September 21, 2023 quoting "*Glenmark Life Sciences gains on parent Glenmark Pharma plan to pare stake*".

In this regard, we request you to refer to the Company's disclosures dated September 21, 2023 pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, in relation to (i) outcome of the board meeting held on September 21, 2023; (ii) the press release titled "*Glenmark Pharma announces proposed divestment of majority stake in Glenmark Life Sciences*"; and (iii) the investor presentation titled "*Glenmark Pharma announces proposed divestment of majority stake in Glenmark Life Sciences*", uploaded on the websites of the BSE and the NSE earlier today.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited

Harish Kuber
Company Secretary & Compliance Officer

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099

T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com